Effects of Vadadustat on Anemia, Quality of Life, and Inflammation in Dialysis Patients

This is a two-period, two-sequence crossover study in patients receiving maintenance peritoneal dialysis. All participants remain on background darbepoetin alfa therapy throughout the study. The study compares add-on vadadustat plus background darbepoetin alfa with background darbepoetin alfa alone, with each treatment period lasting 8 weeks and separated by a 4-week washout period. Monthly laboratory assessments and dialysis adequacy measurements will be performed to evaluate anemia control, quality of life, inflammation, and dialysis adequacy.

NCT Number	NCT07537816
Lead Sponsor	Mackay Memorial Hospital
Conditions	Renal Anemia
Enrollment	40 participants
Start Date	2026-04-15
Primary Completion	2026-09-30 (estimated)
Study Completion	2026-10-15 (estimated)
Updated on ClinicalTrials.gov	2026-04-23